Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.42 |
| ▸ | KIF11 | P52732 | 6/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31142119 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KIF11NPSR1 | |
| SCHEMBL31096183 | 0.92 | MME (0.43) | SLC1A3SLC1A2SLC1A1KIF11NPSR1 | |
| SCHEMBL30811214 | 0.91 | MME (0.41) | SLC1A3SLC1A2SLC1A1MME | |
| SCHEMBL30787544 | 0.90 | NPSR1 (0.53) | NPSR1MME | |
| SCHEMBL31720094 | 0.86 | CTRB1 (0.40) | NPSR1MME | |
| SCHEMBL27429550 | 0.86 | ECE1 (0.39) | SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL30814959 | 0.84 | ACE (0.36) | KIF11 | |
| SCHEMBL30815070 | 0.84 | ACE (0.36) | KIF11 | |
| SCHEMBL31142112 | 0.84 | CYP1A2 (0.39) | NPSR1MME | |
| SCHEMBL25209459 | 0.84 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4337270-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | SLC1A3 3186/4885SLC1A2 3853/4885SLC1A1 3447/4885 |
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | SSTR1, SSTR3, SSTR4 | SLC1A3 45/4885SLC1A2 87/4885SLC1A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.